Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria.

Moritz Schroll, Yacine Amar, Peter Krüger, Klaus Neuhaus, Karima Djabali

Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany. · pubmed

Paper

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is a fatal genetic disorder caused by progerin, a mutant lamin A variant that disrupts nuclear architecture and drives systemic cellular dysfunction. Gastrointestinal (GI) involvement in HGPS remains poorly understood, despite growing evidence of gut abnormalities and microbial dysbiosis in progeroid mouse models. Here, we provide the first comprehensive characterization of colonic pathology in Lmna

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that Baricitinib enhances Lonafarnib therapy to maintain colonic homeostasis and microbial balance in a progeroid mouse model. This research addresses gastrointestinal issues related to a genetic disorder of aging, contributing to the understanding of aging mechanisms and potential interventions.

Author of this paper? Send a correction.